Abstract:Protein glycosylation is the co‐ and/or post‐translational modification of proteins with oligosaccharides (glycans). This process is not template based and can introduce a heterogeneous set of glycan modifications onto substrate proteins. Glycan structures preserve biomolecular information from the cell, with glycoproteins from different cell types and tissues displaying distinct patterns of glycosylation. Several decades of research have revealed that glycan structures also differ between normal physiology and disease. This suggests that the information stored in glycoproteins and glycans can be utilized for disease diagnosis and monitoring. Methods that enable sensitive and site‐specific measurement of protein glycosylation in clinical settings, such as nano‐flow liquid chromatography tandem mass spectrometry, are therefore essential. The purpose of this perspective is to discuss recent advances in mass spectrometry and the potential of these advances to facilitate the detection and monitoring of disease‐specific glycoprotein glycoforms. Glycoproteomics, the system‐wide characterization of glycoprotein identity inclusive of site‐specific characterization of carbohydrate modifications on proteins, and glycomics, the characterization of glycan structures, will be discussed in this context. Quantitative measurement of glycopeptide markers via parallel reaction monitoring is highlighted. The development of promising glycopeptide markers for autoimmune disease, liver disease, and liver cancer is discussed. Synthetic glycopeptide standards, ambient ionization mass spectrometry, and consideration of glyco‐biomarkers in two‐ and three‐dimensional space within tissue will be critical to the advancement of this field. The authors envision a future in which glycoprotein mass spectrometry workflows will be integrated into clinical settings, to aid in the rapid diagnosis and monitoring of disease.

Mass spectrometry-based N-glycoproteomic approaches and their applications in cancer research

Mass Spectrometry-Based N-glycoproteomics for Cancer Biomarker Discovery.

Glycosylation in the Tumor Immune Response: the Bitter Side of Sweetness

Progress of Proteomics Driven Precision Medicine-From a Glycosylation View.

Mass Spectrometry-Assisted Gel-Based Proteomics In Cancer Biomarker Discovery: Approaches And Application

Protein glycosylation in lung cancer from a mass spectrometry perspective

Aberrant Glycosylation And Cancer Biomarker Discovery: A Promising And Thorny Journey

Mass spectrometry-based structure-specific N- glycoproteomics and biomedical applications

Biomarker Discovery via N-Glycoproteomics

Altered glycosylation in cancer: molecular functions and therapeutic potential

Advancements in mass spectrometry-based glycoproteomics and glycomics

Glycomic technology and its application in disease marker mining

Validation and Development of N-glycan As Biomarker in Cancer Diagnosis

Decoding the glycoproteome: a new frontier for biomarker discovery in cancer

N-glycan, a biomarker in current cancer diagnosis

Unlocking the Future of Colorectal Cancer Detection: Advances in Screening Glycosylation-Based Biomarkers on Biological Mass Spectrometry Technology

Analysis of N-Glycoproteins Using Genomic N-Glycosite Prediction

Mass Spectrometry-based Strategies and Methods for N-linked Intact Glycopeptide Analysis

Application Of Lectin Affinity Methods In Analysis And Detection Of Glycoprotein Cancer Biomarkers

Recent Progress in Quantitative Glycoproteomics.

Clinical glycoprotein mass spectrometry: The future of disease detection and monitoring